Patterns of prostate-specific antigen testing by remoteness of residence and socio-economic status: An Australian population-based study.


Journal

The Australian journal of rural health
ISSN: 1440-1584
Titre abrégé: Aust J Rural Health
Pays: Australia
ID NLM: 9305903

Informations de publication

Date de publication:
Jun 2019
Historique:
received: 13 11 2017
revised: 04 02 2019
accepted: 05 02 2019
pubmed: 10 5 2019
medline: 21 12 2019
entrez: 10 5 2019
Statut: ppublish

Résumé

Describes the variation in prostate cancer testing by the remoteness of residence and socio-economic status groups in Australia. A national population-based descriptive study using Medicare data extracted by the Department of Health (formerly the Department of Health and Ageing). Australia. All men, with a Medicare-reimbursed prostate-specific antigen test conducted in Australia between 2002 and 2017, were included. We focused on "screening and case finding" tests (Medicare Benefits Schedule item number 66655) from 1 April 2005 to 31 December 2009, to describe testing differences in subgroups. Groups were categorised into State and Territory, socio-economic status and region of residence. A negative binomial regression model was fitted to measure the incidence rate ratios of those who had a screening prostate-specific antigen test by group. Age-standardised testing rates and incidence rate ratios. Between 2002 and 2017, 11 588 775 screening prostate-specific antigen tests were reimbursed by the Department of Human Services. During 2005-2009, 52% of all Australian men, aged 40 years and over, had a screening test. The incidence rate ratios differed by State and Territory. Men aged 40 years and over, living in very remote areas, were 43% less likely to have had a screening test than residents of major cities. Prostate-specific antigen testing rates fell in all age groups between 2007 and 2009 and 2017. The prostate-specific antigen testing behaviour differs between community groups in Australia. Men were less likely to have had a screening prostate-specific antigen test the farther they lived from the major cities. This highlights the need for a more targeted approach to achieve an equitable and evidence-based prostate cancer care across all sectors of the community.

Identifiants

pubmed: 31070837
doi: 10.1111/ajr.12504
doi:

Substances chimiques

Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Journal Article

Langues

eng

Pagination

216-223

Subventions

Organisme : Prostate Cancer Foundation of Australia
ID : NCG 4513
Organisme : National Health and Medical Research Council
ID : 1016598

Informations de copyright

© 2019 National Rural Health Alliance Ltd.

Auteurs

Ross J S Calopedos (RJS)

Cancer Research Division, Cancer Council NSW, Sydney, New South Wales, Australia.
Gosford Hospital, Gosford, New South Wales, Australia.

Albert Bang (A)

Cancer Research Division, Cancer Council NSW, Sydney, New South Wales, Australia.

Peter Baade (P)

Cancer Research Centre, Cancer Council Queensland, Brisbane, Queensland, Australia.
School of Mathematical Sciences, Queensland University of Technology, Brisbane, Queensland, Australia.
Menzies Health Institute Queensland, Griffith University, Southport, Queensland, Australia.

Xue Q Yu (XQ)

Cancer Research Division, Cancer Council NSW, Sydney, New South Wales, Australia.
Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.

Stephen Ruthven (S)

Gosford Hospital, Gosford, New South Wales, Australia.

Manish I Patel (MI)

Discipline of Surgery, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
Department of Urology, Westmead Hospital, Westmead, New South Wales, Australia.

David P Smith (DP)

Cancer Research Division, Cancer Council NSW, Sydney, New South Wales, Australia.
Menzies Health Institute Queensland, Griffith University, Southport, Queensland, Australia.
Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH